Evaluation and medical management of erectile dysfunction

Mayo Clinic Proceedings

Volumn 81, Issue 3, 2006, Pages 385-390

  Beckman, Thomas J ^a   Abu Lebdeh, Haitham S ^a   Mynderse, Lance A ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; METHYLTESTOSTERONE; NITRATE; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; TAMSULOSIN; TESTOSTERONE; VARDENAFIL;

ARTHRALGIA; BACKACHE; CARDIOVASCULAR RISK; CLINICAL FEATURE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HALF LIFE; DYSPEPSIA; EDEMA; ERECTILE DYSFUNCTION; FLUSHING; GENITAL PAIN; GYNECOMASTIA; HEADACHE; HEPATITIS; HORMONAL THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTENSION; INFERTILITY; LIMB PAIN; LIVER TUMOR; MALE; MYALGIA; NAUSEA; NOSE CONGESTION; OBSTRUCTIVE JAUNDICE; PATHOGENESIS; PENIS ERECTION; PHYSICAL EXAMINATION; POLYCYTHEMIA; PRIAPISM; PROSTATE CARCINOMA; PSYCHOLOGICAL ASPECT; RETINITIS PIGMENTOSA; REVIEW; RHINITIS; SIDE EFFECT; SLEEP APNEA SYNDROME; STOMACH DISCOMFORT; SYNCOPE; URETHRAL PAIN; VISUAL DISORDER;

EID: 33644694941     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.3.385     Document Type: Review

References (34)

1. Morgentaler A. A 66-year-old man with sexual dysfunction. JAMA. 2004;291:2994-3003.
2. NIH Consensus Development Panel on Impotence. NIH Consensus Conference: impotence. JAMA. 1993;270:83-90.
3. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors [published correction appears in JAMA. 1999;281:1174]. JAMA. 1999;281:537-544.
4. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61.
5. Spark RF, White RA, Connolly PB. Impotence is not always psychogenic: newer insights into hypothalamic-pituitary-gonadal dysfunction. JAMA. 1980;243:750-755.
6. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev. 1995;75:191-236.
7. Fowler CI. The neurology of male sexual dysfunction and its investigation by clinical neurophysiological methods. Br J Urol. 1998;81:785-795.
8. Naylor AM. Endogenous neurotransmitters mediating penile erection. Br J Urol. 1998;81:424-431.
9. Corbin JD, Francis SH, Webb DJ. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology. 2002;60(2, suppl 2):4-11.
10. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med. 1992;326:90-94.
11. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75:725-748.
12. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the health professions follow-up study. Ann Intern Med. 2003;139:161-168.
13. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol. 2000; 163:460-463.
14. Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004; 291:2978-2984.
15. Wein AJ, Van Arsdalen KN. Drug-induced male sexual dysfunction. Urol Clin North Am. 1988;15:23-31.
16. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (UEF): a multidimensional scale for assesment of erectile dysfunction. Urology. 1997;49:822-830.
17. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil: a novel effective oral therapy for male erectile dysfunction. Br J Urol. 1996;78:257-261.
18. Flower R. Lifestyle drugs: pharmacology and the social agenda. Trends Pharmacol Sci. 2004;25:182-185.
19. Potts A, Grace V, Gavey N, Vares T. "Viagra stories": challenging 'erectile dysfunction.' Soc Sci Med. 2004;59:489-499.
20. Low WY, Zulkifli SN, Wong YL, Tan HM. What Malaysian women believe about Viagra: a qualitative inquiry. Aging Male. 2002;5:57-63.
21. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (VIAGRA™) in the treatment of erectile dysfunction. Int J Impot Res. 1998;10:69-73.
22. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA. 2002;287:719-725.
23. DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol. 2000;86:175-181.
24. Hermann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med. 2000;342:1622-1626.
25. Wysowski DK, Farinas E, Swartz L. Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol. 2002;89:1331-1334.
26. McCullough AR, Barada JH, Fawzy A, Guay AT, Hatzichristou D. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology. 2002;60(2, suppl 2):28-38.
27. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA, Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction [published correction appears in N Engl J Med. 1998;339:59]. N Engl J Med. 1998;338:1397-1404.
28. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease [published correction appears in J Am Coll Cardiol. 1999;34:1850]. J Am Coll Cardiol. 1998;33:273-282.
29. McVary KT, McKenna KE. The relationship between erectile dysfunction and lower urinary tract symptoms: epidemiological, clinical, and basic science evidence. Curr Urol Rep. 2004;5:251-257.
30. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al, Medicated Urethral System for Erection (MUSE) Study Group. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med. 1997;336:1-7.
31. Govier FE, McClure RD, Weissman RM, Gibbons RP, Pritchett TR, Kramer-Levien D. Experience with triple-drug therapy in a pharmacological erection program. J Urol. 1993;150:1822-1824.
32. Virag R, Shoukry K, Floresco J, Mollet F, Greco E. Intercavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J Urol. 1991;145:287-292.
33. O'Carroll R, Bancroft J. Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. Br J Psychiatry. 1984;145:146-151.
34. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Endocr Pract. 2002;8:440-456.